(GILD) Gilead Sciences Inc. – Momentum – Zacks Rank Buy
Gilead Sciences Inc. (GILD) continues to grow its earnings in a tough market on the strength of its HIV drug franchise. Gilead’s fourth-quarter results, reported on Jan 29, were once again of expectations.
Revenue was up 30% from last year to $1.43 billion. Earnings came in at 60 cents per share, 5 cents ahead of the consensus estimate. This was Gilead’s second consecutive earnings surprise.
Estimates Tick Higher
After the solid quarter, analysts went ahead and lifted their earnings projections. The current-year estimate is up 11 cents to $2.51 per share. The next-year estimate is bullish, pegged at $2.86, a 14% earnings growth projection.
The Chart
In spite of Gilead’s great quarter, market pressure has weighed on the company’s share price after encountering some short-term resistance just above the $53 mark. Take a look below.

Zacks Investment Research
View original at: Zacks.com News Feed
Similar Posts: GILD | Gilead Sciences Incorporated | Biotechnology | Healthcare
RSS feeds:
GILD | Gilead Sciences Incorporated | Biotechnology | Healthcare |
Other Posts by vitalstocks | RSS Feed for this author